Tower Research Capital (TRC)’s Avita Medical RCEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$163K Buy
13,885
+11,612
+511% +$92.1K ﹤0.01% 2503
2026
Q2
$9.39K Sell
2,273
-1,756
-44% -$7.57K ﹤0.01% 4028
2026
Q1
$14.9K Buy
4,029
+717
+22% +$3.01K ﹤0.01% 3687
2025
Q4
$11.4K Sell
3,312
-2,950
-47% -$11.8K ﹤0.01% 3597
2025
Q3
$32K Buy
6,262
+2,103
+51% +$11K ﹤0.01% 2888
2025
Q2
$22K Buy
4,159
+2,712
+187% +$19.7K ﹤0.01% 3626
2025
Q1
$11.8K Sell
1,447
-277
-16% -$2.59K ﹤0.01% 3505
2024
Q4
$22.1K Buy
1,724
+271
+19% +$3.2K ﹤0.01% 3112
2024
Q3
$15.6K Sell
1,453
-3,548
-71% -$33.3K ﹤0.01% 3407
2024
Q2
$39.6K Buy
5,001
+4,753
+1,917% +$45.2K ﹤0.01% 3273
2024
Q1
$3.98K Sell
248
-7,097
-97% -$115K ﹤0.01% 4760
2023
Q4
$101K Buy
7,345
+6,797
+1,240% +$77.9K ﹤0.01% 2640
2023
Q3
$8.01K Sell
548
-76
-12% -$1.29K ﹤0.01% 4408
2023
Q2
$10.6K Buy
+624
New +$9.16K ﹤0.01% 4094
2023
Q1
– Sell
-3,464
Closed -$23K – 6194
2022
Q4
$23K Buy
3,464
+1,845
+114% +$11.1K ﹤0.01% 3003
2022
Q3
$9K Sell
1,619
-9,774
-86% -$60.4K ﹤0.01% 4682
2022
Q2
$54K Buy
11,393
+10,415
+1,065% +$64.3K ﹤0.01% 2809
2022
Q1
$8K Sell
978
-943
-49% -$8.69K ﹤0.01% 4611
2021
Q4
$23K Sell
1,921
-1,341
-41% -$20.4K ﹤0.01% 3524
2021
Q3
$58K Buy
3,262
+2,183
+202% +$41.2K ﹤0.01% 2829
2021
Q2
$22K Buy
+1,079
New +$21.3K ﹤0.01% 3812
2021
Q1
– Sell
-654
Closed -$12K – 5660
2020
Q4
$12K Sell
654
-1,044
-61% -$22.9K ﹤0.01% 4209
2020
Q3
$43K Buy
1,698
+1,422
+515% +$35.4K ﹤0.01% 3597
2020
Q2
$8K Buy
+276
New +$8.44K ﹤0.01% 4117

Other funds holding RCEL

Tower Research Capital (TRC)'s RCEL Position: Q3 2026 in Review

Tower Research Capital (TRC) increased its Avita Medical (RCEL) stake by 511% in Q3 2026, buying an estimated $92.1K and bringing the position to 13,885 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #2503.

Tower Research Capital (TRC) first reported a position in RCEL in Q2 2020 and has held it in 24 quarters since. 89 funds tracked by Wall St. Rank hold RCEL as of Q3 2026.

  • Tower Research Capital (TRC) held 13,885 shares of Avita Medical worth $163K as of Q3 2026.
  • Tower Research Capital (TRC) bought 11,612 Avita Medical shares in Q3 2026, an estimated $92.1K.
  • Avita Medical made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #2503 holding.
  • Tower Research Capital (TRC) first reported a position in Avita Medical in Q2 2020 and has held it in 24 quarters since.
  • 89 funds tracked by Wall St. Rank held Avita Medical as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.